SCHEMBL3735477

SCHEMBL3735477

CN(C)c1c(N2CCc3ccc(NC(=O)c4sccc4NCc4ccnc5ccccc45)cc32)c(=O)c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.52
RET P07949 3/20 0.52
KIT P10721 2/20 0.52
RAF1 P04049 1/20 0.52
LCK P06239 1/20 0.52
CYP3A4 P08684 1/20 0.52
MAP3K20 Q9NYL2 1/20 0.52
RIPK3 Q9Y572 1/20 0.52
FLT1 P17948 4/20 0.41
HTR2C P28335 2/20 0.38
HTR2B P41595 2/20 0.38
BRAF P15056 1/20 0.36
MAPK8 P45983 1/20 0.34
MAPK9 P45984 1/20 0.34
MAPK10 P53779 1/20 0.34
ABCB1 P08183 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.34
MALT1 Q9UDY8 1/20 0.33
MAPK14 Q16539 1/20 0.33
FAAH O00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13043373 0.94 KDR (0.52) KDRRETKITRAF1LCK
SCHEMBL3740356 0.92 KDR (0.52) KDRRETKITRAF1LCK
SCHEMBL3729995 0.91 KDR (0.52) KDRRETKITRAF1LCK
SCHEMBL3741822 0.91 KDR (0.54) KDRRETKITRAF1LCK
SCHEMBL3735420 0.90 KDR (0.52) KDRRETKITRAF1LCK
SCHEMBL3731986 0.90 KDR (0.52) KDRRETKITRAF1LCK
SCHEMBL3735048 0.90 KDR (0.53) KDRRETKITRAF1LCK
SCHEMBL3738455 0.90 KDR (0.51) KDRRETKITRAF1LCK
SCHEMBL3735050 0.90 KDR (0.51) KDRRETKITRAF1LCK
SCHEMBL3735779 0.89 KDR (0.51) KDRRETKITRAF1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060111349-A1 (Arylamidoaryl)squaramide compounds OSI PHARMACEUTICALS, INC. 2006-05-25 US claimed
WO-2006034111-A1 (ARYLAMIDOARYL)SQUARAMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2006-03-30 WO claimed
US-7829717-B2 (Arylamidoaryl)squaramide compounds OSI PHARMACEUTICALS, INC. (US) 2010-11-09 US disclosed
US-20060111349-A1 (Arylamidoaryl)squaramide compounds OSI PHARMACEUTICALS, INC. 2006-05-25 US disclosed
WO-2006034111-A1 (ARYLAMIDOARYL)SQUARAMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111349-A1 (Arylamidoaryl)squaramide compounds KIT, TSSK6, MCTS1 KDR 1120/4885RET 553/4885KIT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.